Epithelial ovarian cancer is the leading cause of death among gynecological malignancies. Platinum resistance remains a dilemma and bottleneck in treatment, and salvage chemotherapy has limited effectiveness. Recently, the role of secondary cytoreductive surgery (SCS) in patients with platinum-resistant recurrent ovarian cancer (ROC) has caused attention especially in patients with oligometastases. However, there is neither high-quality evidence-based evidence nor standardized criteria for selecting SCS for patients with platinum-resistant ROC until now.

中文翻译：

---

三线复发内铂耐药卵巢癌患者二次细胞减灭术的评估：一项多中心、随机对照研究。

上皮性卵巢癌是妇科恶性肿瘤中死亡的主要原因。铂类耐药仍然是治疗的困境和瓶颈，挽救性化疗的效果有限。最近，二次细胞减灭术（SCS）在铂耐药复发性卵巢癌（ROC）患者中的作用引起了人们的关注，尤其是寡转移患者。然而，迄今为止，尚无高质量的循证证据，也没有标准化的标准为铂类耐药 ROC 患者选择 SCS。